Add BrightSurf on Google Email

Science News for May 3, 2015


Study shows where damaged DNA goes for repair

Researchers discovered that damaged DNA with expanded CAG repeats relocate to the periphery of the cell nucleus for repair. This shift is crucial in preventing repeat instability and genetic disease.

SourceTufts University·JournalGenes & Development·DateMay 3, 2015

Study: Generic transplant drugs as good as brand name

A study by researchers at the University of Cincinnati has found that generic formulations of tacrolimus are bioequivalent to the name-brand version, suggesting they can be used interchangeably post-transplant. The findings have important implications for immunosuppressant drug management and patient care.

SourceUniversity of Cincinnati·DateMay 3, 2015

NIH-funded study points way forward for retinal disease gene therapy

Gene therapy for Leber congenital amaurosis improves vision and retina sensitivity within weeks of treatment, with peak benefits after one to three years. However, these gains diminish over six years, revealing the need for further research to sustain restored vision.

SourceNIH/National Eye Institute·JournalNew England Journal of Medicine·DateMay 3, 2015

New test predicts sudden cardiac death in hemodialysis patients

A new test has been developed to predict sudden cardiac death in hemodialysis patients, combining nuclear medicine, C-reactive protein, and electrocardiogram (ECG). Patients with 2 or 3 abnormal measures were at a significantly increased risk of cardiac death.

SourceEuropean Society of Cardiology·DateMay 3, 2015
Apple iPhone 17 Pro

Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.

Gene therapy efficacy for LCA: Improvement is followed by decline in vision

A new study demonstrates that gene therapy for Leber congenital amaurosis (LCA) improves vision in patients within weeks of treatment, with benefits peaking at one to three years after treatment. However, the visual gain eventually declines, highlighting the need for future therapeutic strategies to sustain restored vision.

SourceUniversity of Pennsylvania School of Medicine·JournalNew England Journal of Medicine·DateMay 3, 2015